行情

CARA

CARA

Cara
NASDAQ

实时行情|Nasdaq Last Sale

21.44
+0.01
+0.05%
已收盘, 16:49 11/14 EST
开盘
21.28
昨收
21.43
最高
21.51
最低
21.05
成交量
26.41万
成交额
--
52周最高
27.55
52周最低
12.19
市值
10.01亿
市盈率(TTM)
-8.9606
分时
5日
1月
3月
1年
5年

分析师评级

9位分析师的综合评级

买入

免责声明:分析师观点仅供投资者决策参考,不构成任何买卖投资建议。

EPS

CARA 新闻

  • 谷歌公司计划推出个人支票账户
  • 新华网.30分钟前
  • MuleSoft以65亿美元价格被Salesforce收购
  • 新浪财经-自媒体综合.37分钟前
  • 京东盘前大涨5.33%:2019Q3净利31亿元 同比增长160%
  • 新浪科技.51分钟前
  • 京东2019第三季度移动端月活跃用户数同比增长36%
  • 新浪科技.1小时前

更多

所属板块

生物技术和医学研究
-0.05%
制药与医学研究
-0.27%

热门股票

名称
价格
涨跌幅

CARA 简况

Cara Therapeutics, Inc. is a clinical-stage biopharmaceutical company. The Company is focused on developing and commercializing chemical entities designed to alleviate pain and pruritus by focusing on kappa opioid receptors. It is developing a class of product candidates that target the body's peripheral nervous system. The Company operates through the activities related to the discovery and development of therapeutics to treat serious medical conditions, including pain and pruritus. Its product candidate pipeline includes I.V. CR845 for acute pain; I.V. CR845 for uremic pruritus; Oral CR845 for acute and chronic pain, and CR701 for neuropathic and inflammatory pain. I.V. CR845 is an injectable version of peripheral kappa opioid receptor agonist, which is intended for the treatment of acute pain in an acute care setting. CR845 has exhibited anti-pruritic, or anti-itch, potency in standard preclinical models.
展开

Webull提供Cara Therapeutics Inc的股票价格,实时市场报价,专业分析师评级,深度图表和免费的股票新闻,以帮助您做出投资决策。